HYPERTROPHIC CARDIOMYOPATHY: AN OVERVIEW

Abstract

Hypertrophic cardiomyopathy (HCM) is considered the most common hereditary heart disease. It is characterized by marked variability in the morphological expression and natural history of the disease, ranging from asymptomatic to heart failure or sudden cardiac death. Left ventricular hypertrophy in conjunction with abnormal ventricular configuration results in dynamic obstruction of the left ventricular outflow in most patients. The diagnosis of HCM is based on the presence of non-dilated left ventricular hypertrophy (LVH), which is identified by echocardiography or magnetic resonance imaging, which occurs in the absence of another cardiac, systemic, metabolic or syndromic disease. The objective of pharmacological therapy in HCM is to alleviate symptoms through pharmacotherapy and septal reduction therapies. In this review, relevant clinical issues and treatment options for HCM were summarized.